ArticleScientific reports2018

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.

Daksh Thaper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.